Novo Nordisk Has Probably Declined Enough
Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is ...
NVO INVESTOR DEADLINE: Novo Nordisk Investors are Alerted to Contact BFA Law before the Imminent March 25 Class Action Deadline
New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...
Obesity drug sales surge at Novo Nordisk
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.